Patent 8207179 was granted and assigned to Boehringer Ingelheim on June, 2012 by the United States Patent and Trademark Office.
The present invention encompasses compounds of general Formula (1) wherein R2, R3, Q, W, X, Y and Z are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.